Non-small Cell Lung Cancer research hub
5 indexed studies · 4 currently recruiting
- recruitingPHASE1, PHASE2
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
This study is testing a new medicine called S241656 for people with certain advanced cancers, including lung, bowel, and pancreatic cancers. It aims to find a safe and effective dose, either alone or with other treatments, for cancers with specific genetic changes.
United States · Denmark · Hong Kong - active not recruitingPHASE2
Datopotamab Deruxtecan (Dato-DXd, DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer
This study looks at a new drug, DS-1062a, for people with advanced lung cancer that has spread or can't be removed by surgery. We want to see how well it works and if it's safe for those who haven't responded to previous treatments.
France - recruiting
Description of Neurocognitive and Psychiatric Disorders Associated With Targeted Therapies Used in the Treatment of Lung Cancers With ALK/ROS1 Fusion and Their Impact on Patients' Quality of Life: Construction of an Experimental Patient-researcher Collaborative Care and Research Pathway
This study looks at brain changes, like memory or mood problems, in lung cancer patients taking new targeted medicines. It aims to understand these side effects better and improve care, working with patients.
France - recruitingPHASE1
A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors
This study is testing a new drug called IPH5301 for advanced cancers like breast, stomach, and lung. It's a first-time-in-human study, meaning it's the very first time this drug is being given to people. Researchers want to find a safe dose, either alone or with other treatments.
France - not yet recruitingPHASE1
Pulse Radiotherapy to Overcome Metastatic Immune System Evasion in Lung Cancer
This study looks at a new way to treat advanced lung cancer using special radiation alongside existing immunotherapy. It aims to see if this combination is safe and helps patients whose cancer has grown despite previous treatments.
Canada